Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTB14 in advanced malignant solid tumours
NCT06304818Phase 2Not yet recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Apr 2024
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of SCTB14 in malignant solid tumor, sponsored by Sinocelltech Group Limited. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
SCTB14
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT06304818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06304818.